- Why andropause is underrecognized
- What changes and when
- The physiological consequences
- How this differs from normal aging
- The clinical evaluation
- Treatment approach
- Frequently asked questions
Women have menopause — a defined transition that occurs over a predictable timeline and has an established clinical framework. Men have andropause — a gradual, insidious process that produces a similar constellation of symptoms over a longer period, receives significantly less clinical attention, and is almost never explained to the men experiencing it.
The result is a large number of men in their 40s, 50s, and 60s attributing the changes in their energy, body composition, mood, cognition, and sexual function to "aging" or "stress" when what is actually happening is a measurable, clinically addressable hormonal transition.
Why andropause is underrecognized
The male hormonal transition lacks the clear physiological marker that menopause provides. There is no equivalent of the menstrual cycle ending — no date on a calendar, no biological event that signals the transition has occurred. The decline is gradual: approximately 1 to 2 percent per year beginning around age 30, with acceleration after 40.
Because the change is slow, the symptom onset is slow. Men adapt to gradually declining baseline function without identifying it as a departure from their previous state. The fatigue they have now feels normal because it has been present for two or three years. The weight they carry around their middle has accumulated over a decade. The reduced drive is attributed to the demands of career and family rather than to a hormonal substrate that has quietly shifted.
This is why andropause is underrecognized — not because it is subtle in its effects, but because its gradual onset prevents the kind of dramatic contrast that makes menopause unmistakable.
What changes and when
Testosterone decline is the primary driver of andropause, but it does not occur in isolation. The hormonal landscape of the aging male involves several interconnected changes:
Total testosterone decreases at 1 to 2 percent per year. Cumulative decline over 15 to 20 years is clinically significant — a man at 900 ng/dL at 30 may be at 450 by 50 without any pathology driving the decline beyond the normal aging process.
SHBG increases with age. Sex hormone-binding globulin is the primary testosterone binding protein; as SHBG rises, free testosterone — the biologically active fraction — declines proportionally faster than total testosterone. A man whose total testosterone is declining gradually may experience a more rapid functional decline because his SHBG is simultaneously rising.
Estradiol metabolism changes. As testosterone declines, the aromatase enzyme (which converts testosterone to estrogen) can become disproportionately active, leading to elevated estradiol relative to testosterone. This further reduces effective androgenic activity and produces its own symptom contribution.
Growth hormone and IGF-1 decline in parallel, contributing to the muscle mass loss and recovery impairment that characterize male aging.
The physiological consequences
The symptom cluster of andropause is recognizable once clinicians — and patients — know what to look for:
Energy and fatigue. Persistent, low-level fatigue that is independent of sleep quality. Not tired because of circumstances — tired as a baseline.
Body composition changes. Progressive lean mass loss despite maintained exercise; increasing visceral adiposity, particularly in the midsection. The physique that maintained itself at moderate effort in the 30s requires dramatically more effort — or stops responding.
Cognitive changes. Reduced processing speed, verbal fluency, and the kind of mental sharpness that used to be effortless. Men often notice this in professional settings before they consciously attribute it to hormonal change.
The symptom pattern is recognizable. The evaluation is straightforward.
A comprehensive andropause evaluation at Revitalize identifies whether testosterone optimization is appropriate for your clinical picture.
Check Your Hormone SymptomsSexual function changes. Reduced libido is the most consistent symptom. Erectile changes — reduced firmness, slower response, reduced morning erections — are also common and frequently unreported.
Mood and motivation. The mood pattern of andropause is not typically depression in the classical sense. It is flattening — reduced enthusiasm, lower tolerance for frustration, diminished initiative, loss of the competitive drive that characterized earlier decades.
How this differs from normal aging
This is a question patients frequently ask, and the honest answer is: there is no clean separation. Some degree of testosterone decline is normal. The clinical question is not whether decline has occurred but whether it has crossed the threshold at which it is producing symptoms that meaningfully impair quality of life — and whether those symptoms are addressable.
The clinical framework at Revitalize does not treat a number. It treats a patient whose lab values, symptom burden, and clinical history together indicate that testosterone optimization is likely to produce meaningful improvement.
The clinical evaluation
A comprehensive andropause evaluation includes:
Total testosterone — drawn in the morning when levels peak.
Free testosterone — calculated from total testosterone and SHBG, or direct assay.
SHBG — essential for interpreting free testosterone.
Estradiol — to identify disproportionate aromatase activity.
LH and FSH — to distinguish primary from secondary hypogonadism.
Thyroid panel — TSH, free T3, free T4. Thyroid dysfunction produces an overlapping symptom picture and is common in the same age demographic.
PSA and hematocrit — baseline safety markers before any testosterone intervention.
Treatment approach
Biote pellet therapy delivers testosterone subcutaneously via small pellets that provide steady-state hormone levels over four to five months. The pharmacokinetic profile — no injections, no daily application, no peaks and troughs — is well-suited to the andropausal pattern, which benefits from consistent, physiological testosterone restoration rather than the supraphysiological peaks that some delivery methods produce.
Monitoring is built into the protocol: labs at three to five months post-insertion to verify levels, assess hematocrit, and review estradiol and PSA. Annual monitoring thereafter.
Medical disclaimer: This article is for educational purposes only. Hormone therapy candidacy is determined by clinical evaluation and lab work. Consult a qualified healthcare provider before making treatment decisions.
Travis spent 17+ years in high-acuity clinical medicine — emergency, cardiac ICU, and cath lab — before founding Revitalize. He is a Certified Platinum Biote hormone therapy provider, the published author of You're Not Broken — You're Unbalanced, and the founder of the Rebuild Metabolic Health Institute. His clinical writing reflects the same precision he brought to critical care: specific, honest, and built around what actually works.
